Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421417 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL10145373 | 0.88 | ATM (0.39) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL23895462 | 0.88 | CHRM2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL297706 | 0.87 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL30314505 | 0.87 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL71903 | 0.85 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL71904 | 0.85 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL283443 | 0.85 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL24540373 | 0.85 | CHRM2 (0.46) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL16042463 | 0.85 | CHRM2 (0.46) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | NR1H2 1715/4885CHRM2 225/4885CHRM1 209/4885 |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | NR1H2 66/4885CHRM2 396/4885CHRM1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.